IN8bio (INAB) Competitors $0.16 +0.00 (+2.51%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.17 +0.00 (+1.72%) As of 09:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. APLT, KRON, BLUE, BYSI, GANX, ONCY, NBRV, PDSB, ACRV, and SKYEShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Applied Therapeutics (APLT), Kronos Bio (KRON), bluebird bio (BLUE), BeyondSpring (BYSI), Gain Therapeutics (GANX), Oncolytics Biotech (ONCY), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Acrivon Therapeutics (ACRV), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Applied Therapeutics Kronos Bio bluebird bio BeyondSpring Gain Therapeutics Oncolytics Biotech Nabriva Therapeutics PDS Biotechnology Acrivon Therapeutics Skye Bioscience IN8bio (NASDAQ:INAB) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, institutional ownership, risk and profitability. Do insiders and institutionals believe in INAB or APLT? 92.1% of IN8bio shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 15.5% of IN8bio shares are owned by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in INAB or APLT? Applied Therapeutics received 54 more outperform votes than IN8bio when rated by MarketBeat users. However, 74.29% of users gave IN8bio an outperform vote while only 57.55% of users gave Applied Therapeutics an outperform vote. CompanyUnderperformOutperformIN8bioOutperform Votes2674.29% Underperform Votes925.71% Applied TherapeuticsOutperform Votes8057.55% Underperform Votes5942.45% Is INAB or APLT more profitable? IN8bio's return on equity of -197.15% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets IN8bioN/A -197.15% -130.48% Applied Therapeutics N/A -260.75%-76.04% Which has more volatility and risk, INAB or APLT? IN8bio has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Does the media prefer INAB or APLT? In the previous week, Applied Therapeutics had 4 more articles in the media than IN8bio. MarketBeat recorded 6 mentions for Applied Therapeutics and 2 mentions for IN8bio. IN8bio's average media sentiment score of 1.43 beat Applied Therapeutics' score of 0.49 indicating that IN8bio is being referred to more favorably in the media. Company Overall Sentiment IN8bio Positive Applied Therapeutics Neutral Do analysts prefer INAB or APLT? IN8bio presently has a consensus price target of $6.00, indicating a potential upside of 3,576.47%. Applied Therapeutics has a consensus price target of $6.10, indicating a potential upside of 1,758.62%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts plainly believe IN8bio is more favorable than Applied Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Applied Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, INAB or APLT? IN8bio has higher revenue and earnings than Applied Therapeutics. IN8bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIN8bioN/AN/A-$30.01M-$0.58-0.28Applied Therapeutics-$212K-180.13-$119.76M-$1.61-0.20 SummaryIN8bio beats Applied Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.26M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.2231.0021.7317.82Price / SalesN/A441.16379.2094.61Price / CashN/A168.6838.1534.64Price / Book0.283.476.464.00Net Income-$30.01M-$72.06M$3.20B$247.23M7 Day Performance6.88%3.17%2.86%1.45%1 Month Performance-27.60%-16.97%-8.55%-6.24%1 Year Performance-83.35%-29.07%10.47%0.60% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.5934 of 5 stars$0.16+2.5%$6.00+3,576.5%-84.0%$13.26MN/A-0.2220Short Interest ↓Positive NewsAPLTApplied Therapeutics3.9082 of 5 stars$0.41-5.7%$6.10+1,387.8%-93.5%$47.71M$-212,000.00-0.2530Earnings ReportNews CoverageKRONKronos Bio3.6259 of 5 stars$0.77-1.1%$1.63+110.9%-23.9%$46.98M$9.85M-0.54100Short Interest ↓Positive NewsBLUEbluebird bio2.7102 of 5 stars$4.77-3.6%$44.60+835.0%-78.3%$46.70M$83.81M-0.13520Analyst ForecastGap DownBYSIBeyondSpringN/A$1.15-14.2%N/A-31.3%$46.36M$1.88M0.0080High Trading VolumeGANXGain Therapeutics3.0499 of 5 stars$1.65flat$8.20+397.0%-41.7%$45.85M$50,000.00-1.5020Positive NewsGap UpONCYOncolytics Biotech2.0329 of 5 stars$0.53+6.5%$4.33+721.3%-46.0%$45.60MN/A-1.9530NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PDSBPDS Biotechnology1.5413 of 5 stars$0.96+1.4%$9.00+834.4%-60.6%$43.73MN/A-0.8320Short Interest ↓ACRVAcrivon Therapeutics2.1277 of 5 stars$1.39-7.9%$23.17+1,566.7%-77.6%$43.58MN/A-0.5158Short Interest ↑SKYESkye Bioscience1.0291 of 5 stars$1.39+6.9%$18.00+1,195.0%-86.8%$43.06MN/A-1.9311Analyst RevisionNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies APLT Competitors KRON Competitors BLUE Competitors BYSI Competitors GANX Competitors ONCY Competitors NBRV Competitors PDSB Competitors ACRV Competitors SKYE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INAB Stock Free INAB Stock Alerts